Haemonetics (STU:HAZ) Short-Term Debt: €4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
30 GF Score
Price €74.00
GF Value €74.40
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Haemonetics Short-Term Debt?

Haemonetics STU:HAZ -1.99% 30 Short-Term Debt is €4 Mil as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 30/100 and a GF Value™ of €74.40 (Fairly Valued). The stock has 6 warning signs investors should review.

Haemonetics's Short-Term Debt for the quarter that ended in Mar. 2026 was €4 Mil.

Haemonetics's quarterly Short-Term Debt increased from Sep. 2025 (€259 Mil) to Dec. 2025 (€260 Mil) but then declined from Dec. 2025 (€260 Mil) to Mar. 2026 (€4 Mil).

Haemonetics's annual Short-Term Debt increased from Mar. 2024 (€9 Mil) to Mar. 2025 (€281 Mil) but then declined from Mar. 2025 (€281 Mil) to Mar. 2026 (€4 Mil).

Haemonetics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Haemonetics Short-Term Debt Related Terms

Haemonetics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Haemonetics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Short-Term Debt Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.45 11.01 9.41 280.79 4.34

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.79 263.52 259.29 260.25 4.34
STU:HAZ
30GF Score
Haemonetics Corp STU:HAZ
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €4 Mil mean?
Haemonetics (STU:HAZ) has a Short-Term Debt of €4 Mil as of Mar. 2026.
Is Haemonetics' Short-Term Debt too high?
Haemonetics' current Short-Term Debt is €4 Mil. Overall, Haemonetics has a GF Score™ of 30/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Short-Term Debt compare to IRTC and ITGR?
Haemonetics' Short-Term Debt of €4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Haemonetics's current Short-Term Debt is €4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (STU:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €74.40, compared to a current price of €74.00 — trading 0.5% below its estimated fair value. The current Short-Term Debt is €4 Mil. Haemonetics' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Short-Term Debt is €4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €74.00 is trading 0.5% below its estimated GF Value™ of €74.40. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for STU:HAZ:

  • Short-Term Debt: €4 Mil
  • GF Value™: €74.40 vs. price of €74.00 (0.5% below fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
30GF Score

Get the complete analysis for STU:HAZ

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€74.00
Price
€74.40
GF Value